A Phase I trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of VIT-2763 on iron metabolism and blood levels when administered in single and multiple doses in healthy volunteers

Trial Profile

A Phase I trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of VIT-2763 on iron metabolism and blood levels when administered in single and multiple doses in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs VIT-2763 (Primary)
  • Indications Iron overload
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 14 Feb 2018 New trial record
    • 08 Feb 2018 According to a Vifor Pharma media release, this study will initiate at the beginning of March 2018 and first results from the study are expected in the second half of 2018.
    • 19 Dec 2017 According to a Vifor Pharma media release, a Clinical Trial Application (CTA) for this trial was submitted in November 2017 and approved.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top